Training on the correct use, storage and recording of the readings should be provided by the issuing clinician

MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis Sotagliflozin is not yet available in the NHS, but the company anticipates that it will be available to the NHS in England and Wales within 12 months of guidance publication. Using the latest technology, CareSens N monitors use a highly specific glucose oxidase reagent that will only measure glucose.Medicines suitable for routine use within primary care. Initiation and maintenance of prescribing by Specialists, GPs and other qualified clinicians.

For your patients with diabetes who are currently prescribed Insuman® Basal: A step-by-step guide on how to use Insuman® Basal SoloStar. The CareSens N meets and exceeds the 2013 ISO standards for blood glucose meter accuracy with 99% of results meeting the 2013 accuracy criteria. Sample loading – avoid spoiled testsFor the treatment of patients with Type 2 diabetes who have nocturnal / severe hypoglycaemia or those with recurrent hypoglycaemic episodes requiring hospital admission

The CareSens N meter features a large display and no-skid rubber pads on the meter, so it’s easy to handle.Alogliptin is first choice DPP4- inhibitor. Alogliptin is licensed for use in type 2 diabetes as dual therapy in combination with either metformin, pioglitazone, a sulfonylurea, or insulin (when treatment with these drugs alone fails to achieve adequate glycaemic control); it is also licensed for use as triple therapy in combination with metformin and either pioglitazone or insulin For your patients with diabetes who are currently prescribed Lantus ®: A step-by-step guide on how to use Lantus® SoloStar. For your patients with diabetes who are currently prescribed Toujeo® DoubleStar: A video on how to use Toujeo® DoubleStar.